咸味黏液质型银屑病维医成熟及清除疗法与神经内分泌关联性研究  

Neuroendocrine Correlation of Uyghur Medicine Munziq and Musil for Salty Mucinous Psoriasis

作　　者：赛提阿洪·阿卜力克木 伊力范江·库尔班 买买提江·吐尔逊 李治建 吐尔逊·乌甫尔[1] SAITIAHONG Abulikemu;YILIFANJIANG Kuerban;MAIMAITIJIANG Tuerxun;LI Zhijian;TUERXUN Wufuer(Key Laboratory of Evidence-Based and Transformed Preparation,Xinjiang Hospital of Traditional Chinese Medicine,Hospital of Xinjiang Traditional Uyghur Medicine,Urumqi 830049)

机构地区：[1]新疆维吾尔自治区维吾尔医医院(新疆中药医院制剂循证与转化重点实验室),乌鲁木齐830049

出　　处：《中药药理与临床》2024年第4期101-105,共5页Pharmacology and Clinics of Chinese Materia Medica

基　　金：自治区卫生健康青年医学科技人才专项科研项(编号:WJWY-202220);自治区重点研发专项(编号:2022B03012-3);吐尔逊·乌甫尔全国名老中医药专家传承工作室;自治区天山英才科技创新领军人才项目(编号:2022TSYCLJ0009)。

摘　　要：目的:探讨咸味黏液质型银屑病维医成熟及清除疗法与神经内分泌关联规律,为咸性黏液质型银屑病维医干预治疗提供依据。方法:本项目以37例临床住院咸味黏液质型银屑病病例为研究对象,评价患者治疗前及给予成熟剂和清除剂后证候指标,同时以健康志愿者作为对照,分析患者治疗前及给予成熟剂和清除剂后血清促肾上腺皮质激素释放激素(CRH)、促肾上腺皮质激素(ACTH)和皮质醇(Cortisol)、5-羟色胺(5-HT)和多巴胺(DA)水平。结果:治疗前主症发生频率100%,次症发生频率82.5%;成熟剂治疗后主症发生频率32.5%、次症发生频率35.6%;清除剂治疗后主症发生频率7.5%、次症发生频率9%。治疗各阶段,即成熟剂治疗后皮损严重程度(PASI)评分、生活质量指数(DLQI)评分、银屑病静态临床医生整体评估(PGA)评分显著低于治疗前(P<0.05);清除剂治疗后PASI评分、DLQI评分、SDS评分、PGA评分显著低于治疗前(P<0.05)。成熟剂治疗后总有效率89.1%,清除剂治疗后97.3%,成熟剂治疗后ACTH指标显著低于治疗前(P<0.05);清除剂治疗后ACTH、Cortisol、CRH、5-HT、DA指标显著低于治疗前(P<0.05);而清除剂治疗后DA指标显著低于成熟剂治疗后(P<0.05)。清除剂治疗后有3例患者治疗期出现腹泻、腹胀、恶心等轻度不适,但停药自行缓解。治疗前后血尿常规、肝肾功能均在正常范围之内无明显异常。结论:成熟剂和清除剂治疗后咸味黏液质型银屑病的主症、次症明显改善,尤其给予清除剂作用更明显,这与相关神经内分泌因子调节,恢复患者内环境稳态有关。观察期间受试者未出现过敏反应和不良反应。Objective:To investigate the neuroendocrine correlation of Uyghur medicine Munziq and Musil for salty mucinous psoriasis and to provide a basis for Uyghur medicine treatment of the disease.Methods:Thirty-seven clinically hospitalized patients with salty mucinous psoriasis were included in this study,and the symptom indicators before and after the administration of Munziq and Musil were evaluated.And healthy volunteers served as controls to analyze the serum corticotropin-releasing hormone(CRH),adrenocorticotropic hormone(ACTH),cortisol,5-hydroxytryptamine(5-HT),and dopamine(DA)in patients before and after treatment.Results:Before treatment,the occurrence rate of primary symptoms was 100%,and that of secondary symptoms was 82.5%among the patients.After Munziq treatment,the occurrence rates of primary and secondary symptoms decreased to 32.5%and 35.6%,respectively.Following Musil treatment,these rates further decreased to 7.5%and 9%,respectively.In all treatment stages,scores for the Psoriasis Area and Severity Index(PASI),Dermatology Life Quality Index(DLQI),and Physician Global Assessment(PGA)were lower than those before treatment(P<0.05).The total effectiveness rate was 89.1%after Munziq treatment and 97.3%after Musil treatment.Munziq treatment decreased ACTH(P<0.05),while Musil treatment reduced ACTH,Cortisol,CRH,5-HT,and DA compared with the conditions before treatment(P<0.05),with DA being lower using Musil than Munziq(P<0.05).Three patients experienced mild side effects such as diarrhea,bloating,and nausea after Musil treatment,which resolved without medication.Routine blood and urine indicators,as well as liver and kidney functions remained within normal ranges before and after treatment.Conclusion:The primary and secondary symptoms of salty mucinous psoriasis significantly improved after Munziq and Musil treatment,particularly with the latter.This improvement correlated with the regulation of neuroendocrine factors restoring the patient's internal homeostasis.No allergic reactions or adverse effects were r

关 键 词：维吾尔医 银屑病 成熟剂 清除剂 5-羟色胺 促肾上腺皮质激素释放激素 神经内分泌 

分 类 号：R29[医药卫生—民族医学]